Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

LYRA vs PASG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PASG Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 6–1 Matrix Metrics)

PASG Overall Winner 6-Pillar Tally: LYRA 1 – 3 PASG (2 Tie) Matrix Metrics: LYRA 1 – 6 PASG

As of Nov 17, 2026, Passage Bio, Inc. (PASG) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LYRA carries a Unified Composite Score of 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin), whereas PASG carries 21.6/100 (STRONG SELL) at $4.20 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. PASG 21.6/100 STRONG SELL), PASG captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -25032.0% operating margin) and revenue trajectory (+0.0% vs. -87.2% YoY).
  • Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile PASG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 58.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LYRA vs PASG
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82
PASG NASDAQ Head-to-Head Winner
Passage Bio, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.20
+1.57% 1D
Market Cap $13.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.69β · 92% Vol
Unified Composite Score
21.6 / 100 STRONG SELL
Tech 3.0 Fund 31.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 58.2 · SMA20: $3.65 · SMA50: $4.09

6-Pillar Scorecard Institutional Category Breakdown (LYRA 1 – 3 PASG)

Columns: Metric · LYRA · PASG
1. Valuation Multiples LYRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.9x N/M
2. Growth & Scale PASG
Revenue Growth (YoY) -87.2% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $600,000 N/A
Market Cap $2.3M $13.7M
3. Profitability & Quality PASG
Gross Margin N/A N/A
Operating Margin -25032.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -404.5% -212.3%
4. Balance Sheet & Cash Flow PASG
Cash Generation (TTM) -$32M EBITDA -$31M
Cash Flow Margin N/A N/A
Net Cash / Leverage -404.5% ROE $28M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 0.0% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LYRA (1) vs PASG (6)
Institutional Metric LYRA PASG Criterion Row Edge
Market Capitalization
Scale
$2.3M $13.7M Larger Scale PASG
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-87.2% +0.0% Higher Growth PASG
Operating Margin (TTM)
Profitability
-25032.0% 0.0% Higher Margin PASG
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-404.5% -212.3% Higher ROE PASG
52-Week Range Position
Momentum
1% ($0–$38) 5% ($3–$20) Stronger Trend PASG
Beta / 30D Volatility
Risk Regime
0.33β · 248% Vol 1.69β · 92% Vol Lower Realized Risk PASG
Unified Institutional Score
Composite Signal
52.2 / 100 (HOLD) 21.6 / 100 (STRONG SELL) Higher Composite LYRA
Trailing 12M Revenue (USD)
Operating Scale
$600,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M EBITDA (-404.5% ROE) -$31M ($28M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PASG +50.01 pp
LYRA: -62.5% · PASG: -12.49%
3M Horizon PASG +59.16 pp
LYRA: -87.62% · PASG: -28.46%
6M Horizon PASG +73.47 pp
LYRA: -87.14% · PASG: -13.67%
1Y Horizon PASG +73.47 pp
LYRA: -87.14% · PASG: -13.67%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LYRA vs PASG. Trailing 12-month operating profitability (LYRA -25032.0% vs PASG 0.0%) and valuation multiples (LYRA N/M vs PASG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LYRA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$600,000
Gross MarginN/A
Op. Margin-25032.0%
ROE / Fwd P/E-404.5% · N/M
PASG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-212.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PASG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.0%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PASG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PASG Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $13.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LYRA vs PASG Key Questions & Quantitative Answers

As of Nov 17, 2026, Passage Bio, Inc. (PASG) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LYRA carries a Unified Composite Score of 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin), whereas PASG carries 21.6/100 (STRONG SELL) at $4.20 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. PASG 21.6/100 STRONG SELL), PASG captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -25032.0% operating margin) and revenue trajectory (+0.0% vs. -87.2% YoY). Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile PASG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 58.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PASG leads the Growth & Scale pillar: LYRA posts -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin), compared with PASG at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LYRA generates $600,000 in USD-normalized revenue versus N/A for PASG. In operating R&D and SG&A reinvestment, LYRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PASG.

LYRA screens cheaper on headline valuation multiples. LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin), whereas PASG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LYRA (-404.5% ROE) versus PASG (-212.3% ROE) capital efficiency.

In options market volatility and institutional positioning, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk). By comparison, PASG carries 0.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.69β · 92% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.